Related Experiment Videos
Epidermal growth factor receptor expression in ameloblastoma
Marilena Vered1, Izhar Shohat, Amos Buchner
1Department of Oral Pathology and Medicine, The Maurice and Gabriela Goldschleger School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel.
Oral Oncology
|January 3, 2003
Summary
Ameloblastoma tumors express Epidermal Growth Factor Receptor (EGFR). This finding supports the potential use of anti-EGFR therapies for treating unresectable ameloblastomas, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Ameloblastoma is a locally aggressive odontogenic tumor with potentially lethal outcomes.
- Current treatment relies on extensive surgical resection.
Purpose of the Study:
- To determine the expression of Epidermal Growth Factor Receptor (EGFR) in ameloblastoma specimens.
- To evaluate the potential of anti-EGFR agents for managing unresectable ameloblastoma cases.
Main Methods:
- Immunohistochemical staining of 58 ameloblastoma specimens using a monoclonal anti-EGFR antibody (clone 31G7).
- Specificity confirmed with positive and negative controls.
- Staining intensity and proportion of stained cells were scored from 0 to 2.
Main Results:
- All 58 ameloblastoma specimens demonstrated EGFR positivity.
- 14% of specimens (8/58) showed maximum EGFR expression (score 2).
- 33% of specimens (19/58) exhibited intermediate EGFR expression (score 1-2).
Conclusions:
- Ameloblastomas are consistently EGFR-positive tumors.
- Targeting EGFR with therapeutic agents could be a viable strategy for reducing tumor size.
- Anti-EGFR therapy may offer a treatment option for unresectable ameloblastomas near vital structures.